Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Postoperative Biomarker Found for Venous Thromboembolism

By LabMedica International staff writers
Posted on 20 Aug 2013
The D-dimer test is often used to rule out the presence of venous thromboembolism, but the test has been considered unreliable in postoperative patients because D-dimer levels may rise after surgery.

The presence of deep vein thrombosis (DVT) or pulmonary embolism (PE), both manifestations of venous thromboembolism, can be detected by performing the D-dimer test. D-dimer is a fibrin degradation product, which is produced when a blood clot or thrombus dissolves.

Scientists at the University of Halle (Germany) conducted a single-center prospective study between April 2010 and February 2012 in patients undergoing elective surgery that involved craniotomy. The study sample consisted of 59 female and 42 male patients ranging in age from 18 to 82 years. Doppler ultrasonography was used to directly detect the presence of thrombus in the patient's lower extremities. If DVT was identified, the location of this disorder was also noted to determine the associated risk of PE.

Plasma levels of D-dimer in all patients were evaluated preoperatively and on the 3rd, 7th, and 10th days postoperatively with the INNOVANCE D-dimer assay (Siemens; Erlangen, Germany). The investigators found that a D-dimer threshold of 2 mg/L indicated venous thromboembolism with a sensitivity of 95.3%, a specificity of 74.1%, a negative predictive value of 95.6%, and a positive predictive value of 73.2%. Only two patients with venous thromboembolism had D-dimer levels lower than 2 mg/L. The D-dimer threshold for PE would appear to be even higher; in this small group of nine patients the mean D-dimer level was 7.14 mg/L.

The authors concluded that using a threshold of 2 mg/L, D-dimer levels will indicate venous thromboembolism in patients after craniotomy with high sensitivity and specificity. Pulmonary embolism seems to be indicated by even higher D-dimer levels. Julian Prell, MD, the lead author, said, “We were honestly surprised by the clarity of our own results, which strongly contradict the established doctrine. Before this study, D-dimer plasma levels were considered to be completely unreliable in the postoperative period. Now, screening for venous thromboembolism using D-dimer plasma levels appears to be very straightforward and clinically applicable.” The study was published on August 6, 2013, in the Journal of Neurosurgery.

Related Links:
University of Halle
Siemens


Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centrifuge
Hematocrit Centrifuge 7511M4
New
TETANUS Test
TETANUS VIRCLIA IgG MONOTEST
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.